Clinical Response to Rhinovirus Challenge

Summary

Participation Requirements

Description

Primary objectives are: To determine whether RV increases expression of interleukin (IL)-25 transcripts by nasal epithelial cells in the asthma and AR but not control cohorts at the peak of infection (days 3 and 4). To determine whether RV increases lower respiratory symptoms in the asthma but not A...

Primary objectives are: To determine whether RV increases expression of interleukin (IL)-25 transcripts by nasal epithelial cells in the asthma and AR but not control cohorts at the peak of infection (days 3 and 4). To determine whether RV increases lower respiratory symptoms in the asthma but not AR and control cohorts. To determine whether asthmatics and allergic rhinitics will demonstrate an increased severity of infection in comparison to control subjects. Secondary objectives are: To determine whether asthmatic and AR cohorts demonstrate increased IL-25 transcript expression over the course of RV infection To determine whether asthmatic and AR cohorts demonstrate increased expression of mRNA transcripts of a type 2 cytokine-inducing profile (IL-33 and thymic stromal lymphopoietin (TSLP)). To determine whether increased transcript expression of this type 2 cytokine-inducing profile can be corroborated as increased expression of protein. To determine whether RV infection in the asthma cohort is associated with increases in biomarkers of inflammation. To determine whether increased severity of RV infection in the asthma and AR cohorts will be associated with more symptoms. To determine whether increased severity of RV infection in the asthma and AR cohorts is related to decreased innate immunity.

Tracking Information